Literature DB >> 11840263

Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.

C Schoch1, S Schnittger, S Bursch, D Gerstner, A Hochhaus, U Berger, R Hehlmann, W Hiddemann, T Haferlach.   

Abstract

For the diagnosis of CML and for monitoring of treatment response the detection of the t(9;22)(q34;q11) or the BCR-ABL rearrangement is necessary. Chromosome banding analysis (CA) is still the gold standard but other techniques like Southern blot, fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) are available. We analyzed 350 CML patients at different stages of disease in parallel with CA, interphase-FISH (IP-FISH), hypermetaphase-FISH (HM-FISH) and RT-PCR. In 20 cases with no Ph(+) metaphases in CA, HM-FISH detected 0.2 to 10% BCR-ABL(+)metaphases. After IP-FISH 107 samples were judged as negative. However, in 17 of these samples HM-FISH detected BCR-ABL(+) metaphases (0.3-11%), and in eight cases CA detected Ph(+) metaphases (2.5-25%). A comparison of IP-FISH performed on uncultivated cells vs cells cultivated for 48 h in 70 cases revealed a higher proportion of BCR-ABL+ cells in the cultivated samples. If nested PCR was negative, all other methods were negative in all cases too. In addition, 94 cases were evaluated using real-time PCR (LightCycler technology). The BCR-ABL/cABL ratio measured showed a high correlation with all other methods. Interestingly, a wide range in the BCR-ABL/ABL ratio was observed especially in patients who showed 100% Ph-positive metaphases in CA. In conclusion, CA, IP-FISH, HM-FISH and real-time PCR give reliable results but differences due to measurement of different target structures have to be kept in mind when using these data for definition of remission status.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840263     DOI: 10.1038/sj.leu.2402329

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  50 in total

Review 1.  Clinical applications of BCR-ABL molecular testing in acute leukemia.

Authors:  Amgad L Nashed; Kathleen W Rao; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

2.  Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations.

Authors:  Tong Zhang; Sylvie Grenier; Bevoline Nwachukwu; Cuihong Wei; Jeffrey H Lipton; Suzanne Kamel-Reid
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

3.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

4.  High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.

Authors:  M-T Krauth; C Eder; T Alpermann; U Bacher; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

5.  Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Tamara Alpermann; Torsten Haferlach
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

6.  Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.

Authors:  Constance Baer; Wolfgang Kern; Sarah Koch; Niroshan Nadarajah; Sonja Schindela; Manja Meggendorfer; Claudia Haferlach; Torsten Haferlach
Journal:  Haematologica       Date:  2016-04-21       Impact factor: 9.941

7.  Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Authors:  M Jawhar; J Schwaab; S Schnittger; K Sotlar; H-P Horny; G Metzgeroth; N Müller; S Schneider; N Naumann; C Walz; T Haferlach; P Valent; W-K Hofmann; N C P Cross; A Fabarius; A Reiter
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

8.  Impact of 9q deletions on the classification of patients with acute myeloid leukemia.

Authors:  Bettina Balk; Torsten Haferlach; Manja Meggendorfer; Wolfgang Kern; Claudia Haferlach; Anna Stengel
Journal:  J Cancer Res Clin Oncol       Date:  2019-03-29       Impact factor: 4.553

9.  MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations.

Authors:  A Stengel; W Kern; M Meggendorfer; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2017-06-08       Impact factor: 11.528

Review 10.  Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.

Authors:  Elias Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.